Blood Lymphocytes in Asthmatics Treated With Therapeutic Proteins
This is an observational, clinic-based, single center study of 120 subjects. Participants will be comprised of patients seen in the outpatient faculty practice in ambulatory care at the UCSF Parnassus campus. Study investigators will enroll 20 healthy participants with no history of lung disease, 50 asthmatics who are newly prescribed therapeutic proteins for their asthma, and 50 asthmatics already being treated with therapeutic proteins for their asthma. Participants will be seen at 1 to 3 visits and provide blood samples at each visit.
• Male or female between the ages of 18 and 80 years at Visit 1 and at least 50% whose age is \>40 years (to ensure age balance among groups and anticipating that groups 1 and 2 will be older).
• Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
• Able to perform reproducible spirometry according to ATS criteria.
• Male or female between the ages of 18 and 80 years at Visit 1
• Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
• Able to perform reproducible spirometry according to ATS criteria.
• Asthma requiring treatment with therapeutic proteins but not yet started on treatment.
• Male or female between the ages of 18 and 80 years at Visit 1
• Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
• Able to perform reproducible spirometry according to ATS criteria.
• Asthma already being treated with therapeutic proteins for at least 6 months.